Table 3 Chi-squared analysis of attitudes towards the disclosure of somatic mutation test results
From: Factors influencing cancer genetic somatic mutation test ordering by cancer physician
Likely to disclose | Likely to not disclose | p-value | |
|---|---|---|---|
Tier 1 and 2 vs Tier 3 | |||
Tier 1 and 2 (average) | 83.3 | 17.2 | < 0.0001* |
Tier 3 | 27 | 62 | |
Tier 2 prognosis | |||
Favourable prognosis | 94 | 7 | 0.0632 |
Unfavourable prognosis | 84 | 15 | |
Tier 2 treatment | |||
Phase II clinical trial | 98 | 5 | < 0.0001* |
Off label | 70 | 30 | |